245P Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Exploratory results of biomarker, updated efficacy and safety analyses from the p
IMforte (NCT05091567) demonstrated statistically significant and clinically meaningful improvements in independently-assessed PFS (stratified HR, 0.54; 95% CI: 0.43, 0.67; P<0.0001) and OS (stratified HR, 0.73; 95% CI: 0.57, 0.95; P=0.0174) with 1L maintenance tx with lurbi + atezo vs atezo in ES-SCLC (CCOD 29 Jul 2024; Paz-Ares Lancet 2025). We report exploratory biomarker and exploratory updated efficacy and safety results.
Authors
- P.F. Simoes da Rocha
- M. Artac
- L. Paz-Ares
- Y-C. Lin
- J.C. Vazquez Limon
- H. Borghaei
- V. Cuchelkar
- M.A.N. Sendur
- M. Majem
- M. Reck
- G. Cai
- K. Bhatt
- S. Peters
- K. Stencel
- K. Syrigos
- M. Srivastava
- D. Chakrabarti
- R.S. Herbst
- S.V. Liu
Institutions
- Fox Chase Cancer Center (US)
- Georgetown University (US)
- National and Kapodistrian University of Athens (GR)
- Georgetown University Medical Center (US)
- Hospital de Sant Pau (ES)
- Centre Hospitalier Universitaire Vaudois (CH)
- Yale University (US)
- Hospital Universitario 12 De Octubre (ES)
- Necmettin Erbakan University (TR)
- Universidad de las Américas (MX)
- Vall d'Hebron Hospital Universitari (ES)
- Kaiser Permanente South San Francisco Medical Center (US)
- Centrum Onkologii (PL)
- LungenClinic Grosshansdorf (DE)
- Ankara Yıldırım Beyazıt University (TR)
- Jazz Pharmaceuticals (Ireland) (IE)
- Atotech (United States) (US)
Publication Details
- Journal
- Immuno-Oncology Technology
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1016/j.iotech.2025.101444
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00